Wire · opportunities
Emerging Psychedelic Therapies for Depression
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 5 October 2026 · Fusion42 review
Psychedelic therapies, including psilocybin (COMP360) and a pharmaceutically optimised LSD (DT120), are advancing through phase 3 trials for treatment-resistant depression and may gain approval by 2027. These therapies show sustained symptom reduction requiring psychotherapy support but face regulatory and clinical feasibility challenges due to their Schedule I classification.
This Wire brief sits within Fusion42's coverage of Mental Health.
◆ ◆ The Wire takeaway
You need to prepare for new therapeutic options that combine psychedelic drugs with psychotherapy, as approval is likely in the US by 2027. This opens a market for treatment-resistant depression but requires adapting to regulatory complexities around Schedule I substances.
◆ Coverage
1 source · 5 Oct 2026
◆ Related on Wire
◆ Topics